FDA OKs BMS' abatacept to prevent GvHD

2021-12-21

Bristol Myers Squibb's Orencia, or abatacept, which treats rheumatoid arthritis, gained the FDA's approval to prevent graft versus host disease, becoming the first FDA-approved drug for GvHD prevention in patients with blood cancer who have undergone a hematopoietic stem cell transplant. Use of the drug could increase the stem cell donor pool through the reduction of the risk for acute GvHD in transplants from unrelated donors.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.